Desrinit, 1 piece, 18 g, 50 mcg/dose, metered nasal spray
When using mometasone for 12 months, there were no signs of atrophy of the nasal mucosa.
A study of biopsy samples of the nasal mucosa revealed that mometasone tended to normalize the histological picture.
When using the drug for a long time (as with any long-term treatment), periodic examination of the nasal mucosa by an otolaryngologist is necessary.
If a local fungal infection of the nose or pharynx develops, it is recommended to stop treatment with the drug and begin specific therapy.
Irritation of the mucous membrane of the nasal cavity and pharynx that persists for a long time is an indication for discontinuation of the drug. With long-term use of the drug, no signs of suppression of the function of the hypothalamic-pituitary-adrenal system were observed. Patients who switch to mometasone therapy after long-term treatment with systemic GCS require special attention. Withdrawal of systemic corticosteroids in such patients may lead to adrenal insufficiency, which may require appropriate measures. During the transition from treatment with systemic corticosteroids to mometasone therapy, some patients may experience withdrawal symptoms of systemic corticosteroids (for example, joint and/or muscle pain, fatigue, depression), despite a decrease in the severity of symptoms associated with damage to the nasal mucosa , such patients must be specifically convinced of the advisability of continuing treatment with Desrinit.
The transition from systemic corticosteroids to local corticosteroids may also reveal pre-existing allergic diseases, such as allergic conjunctivitis and eczema, that were masked by systemic corticosteroid therapy.
The effectiveness and safety of mometasone have not been studied in the treatment of unilateral polyps, polyps associated with cystic fibrosis, and polyps that completely occlude the nasal cavity. Unilateral polyps that are irregular in shape or bleeding should be further examined. Patients undergoing GCS therapy have a reduced immune reactivity and should be warned about the increased risk of infection when contacting patients with certain infectious diseases (for example, chicken pox, measles), as well as the need for medical consultation if such contact occurs.
With long-term use of nasal corticosteroids in high doses, systemic side effects may develop. The likelihood of developing these effects is much less than with the use of systemic corticosteroids and may vary in individual patients, as well as between different corticosteroids. Potential systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataracts, glaucoma, and less commonly, a number of psychological or behavioral effects including psychomotor hyperactivity, sleep disturbance, anxiety, depression, or aggression (especially in children). It is recommended to regularly monitor the growth of children receiving long-term therapy with mometasone. If growth slows, therapy should be reconsidered in order to reduce the dose of mometasone to the minimum effective dose to control the symptoms of the disease. In addition, the patient should be referred to a pediatrician for consultation. Treatment of GCS with higher doses than recommended may lead to clinically significant suppression of adrenal function. If high doses of corticosteroids are known to be used, the possibility of additional use of systemic corticosteroids should be considered during periods of stress or planned surgery.
Impact on the ability to drive vehicles and machinery.
No studies have been conducted to study the effect on the ability to drive vehicles and machinery.
Dezrinit
As with any treatment, patients using mometasone nasal spray dosage form for several months or longer should be periodically examined by a doctor for possible changes in the nasal mucosa.
It is necessary to monitor patients receiving intranasal corticosteroids for a long time. Possible development of growth retardation in children. If growth retardation is detected in children, it is necessary to reduce the dose of intranasal corticosteroids to the lowest that allows for effective control of symptoms. In addition, the patient should be referred to a pediatrician for consultation.
If a local fungal infection of the nose or pharynx develops, it may be necessary to discontinue therapy with mometasone in dosage form - dosed nasal spray and carry out special treatment. Irritation of the mucous membrane of the nose and pharynx that persists for a long time can also serve as a basis for discontinuing treatment with mometasone in dosage form - dosed nasal spray.
In placebo-controlled clinical studies in children, when mometasone in dosage form - nasal spray was used in a daily dose of 100 mcg for a year, no growth retardation was observed in children.
With long-term treatment with mometasone in the dosage form - nasal spray, no signs of suppression of the function of the hypothalamic-pituitary-adrenal system were observed.
Patients who switch to treatment with mometasone in dosage form - a dosage nasal spray after long-term therapy with systemic glucocorticosteroids require special attention. Withdrawal of systemic corticosteroids in such patients can lead to adrenal insufficiency, the subsequent recovery of which may take up to several months. If signs of adrenal insufficiency appear, systemic corticosteroids should be resumed and other necessary measures taken.
When using intranasal corticosteroids, systemic side effects may develop, especially with long-term use in high doses. The likelihood of developing these effects is much less than with the use of oral corticosteroids.
Systemic side effects may vary in individual patients and depending on the glucocorticosteroid drug used. Potential systemic effects include Cushing's syndrome, characteristic Cushingoid signs, adrenal suppression, growth retardation in children and adolescents, cataracts, glaucoma, and less commonly a number of psychological or behavioral effects including psychomotor hyperactivity, sleep disturbance, anxiety, depression, or aggression (especially in children).
During the transition from treatment with systemic glucocorticosteroids to treatment with mometasone nasal spray, some patients may experience initial symptoms of systemic glucocorticosteroid withdrawal (for example, joint and/or muscle pain, fatigue and depression), despite a decrease in the severity of symptoms. associated with damage to the nasal mucosa. If these signs appear, you should resume taking systemic glucocorticosteroids and take other necessary measures. Switching from systemic to topical glucocorticosteroids may also reveal pre-existing allergic diseases such as allergic conjunctivitis and eczema that were masked by systemic glucocorticosteroid therapy.
Patients treated with glucocorticosteroids have a potentially reduced immune responsiveness and should be warned of their increased risk of infection if exposed to patients with certain infectious diseases (eg, chickenpox, measles), as well as the need for medical advice if such exposure occurs .
If signs of a severe bacterial infection appear (for example, fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area), immediate medical consultation is required.
When using mometasone in dosage form - dosed nasal spray for 12 months, there were no signs of atrophy of the nasal mucosa. In addition, mometasone furoate tended to promote normalization of the histological picture when examining biopsy specimens of the nasal mucosa.
The effectiveness and safety of mometasone have not been studied in the treatment of unilateral polyps, polyps associated with cystic fibrosis, and polyps that completely occlude the nasal cavity.
If unilateral polyps of an unusual or irregular shape are detected, especially those that are ulcerated or bleeding, additional medical examination is necessary.
Visual disturbances have been reported with systemic and topical corticosteroid use. If a patient develops symptoms such as blurred vision or other visual disturbances, consider referring the patient to an ophthalmologist to evaluate possible causes, which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR).
When the drug should not be used
It is not recommended to prescribe the drug to breastfeeding mothers or pregnant women. Dezrinit is not used to treat children under two years of age.
Other contraindications for use:
- The presence of individual hypersensitivity to the components that make up Dezrinit.
- Recent surgery on the nose.
- “Fresh” nasal injury. The drug is not prescribed until the wound has completely healed.
The following conditions are not a contraindication, but require special caution when prescribing the drug: any respiratory tract infections, eye damage, prolonged and sluggish inflammation of the nasal mucosa caused by bacterial, fungal or mixed pathogenic flora.
How to use Desrinit to treat adenoids?
Before using the drug for the first time, immediately after opening the bottle, you will need 10 “empty” presses on the dispenser. This must be done in order to establish a stereotypical dose release. At one time, 100 mg of the drug (50 mcg of mometasone) comes out of the dispenser. If the drug is used regularly, then re-calibration is not required. Provided that the bottle has been left inactive for two weeks, it will be necessary to perform ten presses again before using it.
Before introducing the drug into the nasal cavity, shake the bottle vigorously. Before irrigating the nasal cavity, it must be rinsed using saline solution or another antiseptic. The cleaner the nasal passages, the more effective the treatment will be.
As for the dosage, its average values are equivalent to two injections into each nasal passage once per knock. The doctor should select the dosage, as it can be changed depending on the severity of the patient’s condition. If necessary, the frequency of use of the drug is increased to twice a day.
To treat children, you can try starting treatment with a single injection into each nostril, which is repeated once a day. If there is no effect, then perform two injections into each nostril. When the clinical picture can be controlled, the dosage is reduced again.
You can expect the effect of using the drug Dezrinit after 12 hours from the first use.
Important rules for using a bottle of medication to avoid the development of atrophy of the nasal mucosa:
- The bottle is inserted into the nostril strictly vertically.
- Spray the drug into the right nostril with the left hand, and into the left nostril with the right hand.
- The recommended number of injections must not be exceeded.
The drug can be used for a long time. Sometimes it is prescribed for a period of 9 months to a year. This does not affect the effectiveness of the drug, and tissue atrophy is not observed in the nasal passages. For the treatment of adenoids, it is advisable to use the drug in courses of 1-3 months, followed by a break of 1-2 months. Then the course of treatment can be repeated.
Important information
Systemic availability of the drug is less than 0.1%. This means that it practically does not enter the bloodstream and does not spread throughout the body. In this regard, clinical studies were conducted, which made it possible to establish that children who took Dezrinit therapy for a year did not experience any disturbances in growth and development, and the synthesis of corticosteroids by the adrenal glands did not change. The drug cannot be detected in the blood by any available methods.
The mucous membrane of the nasal passages does not undergo atrophic changes during the use of the drug, despite long-term treatment with Dezrinit. However, the use of corticosteroids always carries a risk of tissue atrophy, so periodic examination by an otolaryngologist is mandatory.
If a patient develops a fungal infection while undergoing treatment, then he needs to abandon Desrinitis.
During treatment with Desrinitis, suppression of local immunity is observed. This requires special caution on the part of the patient. He needs to minimize contact with infected people, as the chances of infection increase significantly.
Both children and adults receiving nasal corticosteroid therapy should be under medical supervision.
The drug can be used to treat adenoids in people suffering from bronchial asthma. Moreover, improving nasal breathing in such patients helps stabilize their condition.
Desrinit is not able to fight pathogenic flora. Therefore, if the disease is provoked not only by allergens, but also by viruses, bacteria or fungi, then treatment with specific medications will be required.
An overdose of the drug is unlikely, since its bioavailability is extremely low. However, if a dose significantly exceeding the permissible dose has been administered, it is necessary to consult a doctor and spend some time under the supervision of specialists. No specific measures should be taken.
It is not recommended to simultaneously combine the drug Dezrinit with other drugs from the group of glucocorticosteroids. This can cause adrenal function to be suppressed.
It should be taken into account that the drug cannot be stored for more than 2 months if it has been opened. When the integrity of the packaging is not compromised, the shelf life of the medicinal product is 2 years.
General characteristics of the drug
Desrinit is a nasal spray, which is available in polyethylene bottles equipped with a dispenser. The main active ingredient is mometasone furoate monohydrate, a topical glucocorticosteroid. The drug also contains auxiliary components (polysorbate, citric acid monohydrate, etc.), but they do not have any effect on the course of the disease.
The liquid in the bottle with the medicine is milky in color and is presented as a homogeneous suspension. Vials containing 60 and 140 doses are available for purchase.
Effect of Dezrinit on adenoids
The medicinal properties of the drug Dezrinit are determined by its main active ingredient - mometasone.
The use of a nasal spray for adenoids can achieve the following effects:
- The drug completely blocks the cascade of inflammatory reactions, blocking the production of inflammatory mediators (substances that the body itself synthesizes to fight infection).
- Reducing tissue swelling, facilitating nasal breathing.
- Preventing further destruction of lymphoid tissue.
- Reducing the size of adenoid vegetations, which often avoids surgical intervention. Desrinitis is prescribed even for third-degree adenoids.
- Treatment of secretory otitis media as a complication of adenoids.
- Improved aeration of the paranasal sinuses, spontaneous sanitation of the nasal cavity, unloading of the anastomosis, which was previously blocked by overgrown adenoid tissue.
- Elimination of allergy symptoms.
The drug is prescribed to children who have undergone an adenotomy procedure, which avoids repeated operations.
After local administration of the drug, it is possible to create its maximum concentration in the nasopharynx cavity directly on the adenoids. Therefore, the effect occurs quickly and lasts for a fairly long period of time.
Possible harm
The use of Dezrinit is associated with a number of side effects, although in most cases the drug is well tolerated by patients.
The most common negative health manifestations are: headaches, nosebleeds, a burning sensation in the nasal cavity, and the formation of ulcers on the mucous membrane of the nasal passages.
Allergic reactions in the form of bronchospasm, shortness of breath, angioedema or anaphylactic shock are extremely rare. Rare side effects also include perforation of the nasal septum, irritation of the pharyngeal wall, distortion of the sense of smell and taste, increased intracranial pressure, cataracts or glaucoma.
